Related by context. All words. (Click for frequent words.) 71 MET amplification 69 CGEN # 68 OHR/AVR# 68 favorable pharmacokinetic profile 68 Archexin 68 Ophena TM 68 CYT# potent vascular disrupting 68 potent antitumor activity 67 MGd 67 demonstrated antitumor activity 67 preclinically 67 mGluR2 NAM 67 kidney urologic 67 PSMA ADC 67 MAGE A3 ASCI 67 complete cytogenetic response 67 Symadex 66 Xanafide 66 PhG alpha 1 66 BNC# 66 vivo potency 66 Curaxin CBLC# 66 Aflibercept 66 ENMD # 66 ATL/TV# 66 samalizumab 66 novel VDA molecule 66 CBLC# 66 ALN TTR 66 antitumor efficacy 66 plasma kallikrein inhibitor 66 lenalidomide Revlimid R 66 PROCHYMAL 65 DXL# 65 antiangiogenic activity 65 HGS# 65 NEUGENE 65 ProSavin 65 Onconase 65 Exherin TM 65 Vascugel 65 oral prodrug 65 HQK 65 anticancer activity 65 R#/MEM # 65 Panzem 65 relapsed MM 65 CIMZIA TM 65 #ME# 65 K ras mutations 65 Panzem R 65 OncoVEX GM CSF 65 TG# [003] 65 INCB# [001] 65 CIMZIA ™ 65 angiotensin analog 65 PARP inhibition 65 cannabinor 65 systemically administered 65 Forodesine HCl 65 antiangiogenic agent 65 preclinical efficacy 65 VA# [002] 65 Cethromycin 64 Amplimexon 64 Bezielle 64 oral FTY# 64 PEG SN# 64 NP2 Enkephalin 64 anti amnesic 64 receptor inhibitor 64 antitumor effect 64 Traficet EN 64 Lixivaptan 64 Lisofylline 64 mapatumumab 64 Crizotinib 64 MYDICAR ® 64 immune modulating 64 Panzem R NCD 64 targeted radiotherapeutic 64 GRN# 64 CCR9 64 Seliciclib 64 inhibit metastasis 64 HuLuc# 64 cardiac toxicity 64 alagebrium 64 rhIL 7 64 neurologic progression 64 Tyrima 64 HCV protease inhibitors 64 oral picoplatin 64 SGS# 64 Tesmilifene 64 metaglidasen 64 riociguat 64 Aplidin 64 selective modulator 64 intradermal injection 64 evaluating tivozanib 64 vaccine RiVax TM 64 cMET 64 forodesine 64 XmAb# 64 antiviral potency 64 TOCOSOL Camptothecin 64 Preclinical studies 64 Prodarsan ® 64 antiproliferative effects 64 Golimumab 64 Catena ® 64 JAK inhibitors 64 alvespimycin 64 CEQ# 64 mTOR inhibition 64 CCR9 antagonist 64 antitumor effects 64 OXi# 64 HGS ETR1 mapatumumab 63 Non inferiority 63 vorinostat 63 OMNARIS HFA 63 LAB CGRP 63 Tasimelteon 63 sitaxsentan 63 MTP inhibitors 63 deferiprone 63 taxane refractory 63 UPLYSO 63 Daclizumab 63 Darinaparsin 63 brivaracetam 63 proteasome inhibitor 63 IMA# 63 iroxanadine 63 orally administered inhibitor 63 Angiolix 63 Pemetrexed 63 Omacetaxine 63 Vidofludimus 63 S/GSK# 63 Tß4 63 YONDELIS 63 imexon 63 potent suppressor 63 ZOLINZA 63 trastuzumab Herceptin ® 63 tafamidis 63 MEK inhibitors 63 HGS ETR2 63 SERMs 63 GTC recombinant human 63 SNT MC# 63 viral kinetics 63 ACZ# 63 plus prednisone prednisolone 63 somatostatin analog 63 indibulin 63 Octreolin 63 acetonide FA 63 paliperidone ER 63 ulimorelin 63 acadesine 63 pharmacokinetic PK study 63 huC# DM4 63 VEGF inhibitors 63 CORT # 63 CTAP# Capsules 63 intravascular hemolysis 63 Fibrillex TM 63 mertansine 63 Gleevec resistant 63 bardoxolone methyl 63 R sorafenib tablets 63 vascular disrupting agents 63 CCX# 63 JAK3 63 Teriflunomide 63 sorafenib tablets 63 rxRNA 63 Tarceva TM 63 oral rivaroxaban 63 INCB# [003] 63 CCR2 63 non nucleoside HCV 63 PEGPH# 63 DACH platinum 63 CB2 selective receptor agonist 63 patient derived xenografts 63 Celsentri Selzentry 63 Azedra 63 Phase #b/#a clinical 63 biodistribution studies 63 noscapine 63 refractory prostate cancer 63 IRX 2 63 Fulvestrant 63 ixabepilone 63 DAVANAT 63 CA4P 63 concurrent chemoradiation 62 Afatinib 62 ALGRX 62 thetreatment 62 Virulizin ® 62 telomerase inhibition 62 AQ4N 62 SparVax ™ 62 Spiegelmer ® 62 therapeutic monoclonal antibody 62 fosbretabulin 62 Protectan CBLB# 62 MVA BN R 62 omega interferon 62 Vicinium TM 62 iSONEP 62 Hsp# Inhibitor 62 efaproxiral 62 ONCONASE R 62 levodopa induced dyskinesia 62 Pharmacokinetic studies 62 flavopiridol 62 #D#C# 62 p# inhibitor 62 pain palliation 62 statistically significant efficacy 62 STAT3 signaling 62 EZN 62 Durezol 62 immune modulatory 62 Curaxin 62 Telintra 62 Interferon alpha 62 palifermin 62 Inosine 62 Revascor ™ 62 depsipeptide 62 histone deacetylase inhibitor 62 Aeroquin 62 menadione 62 NV1FGF 62 OMP #M# 62 EndoTAG TM -1 62 LT NS# 62 pomalidomide 62 endothelin antagonist 62 GAP #B# 62 Resten NG 62 delta isoform 62 favorable tolerability 62 vitro potency 62 Zolinza 62 HER2 overexpression 62 hereditary deficiency 62 TYZEKA 62 allogeneic HSCT 62 teriflunomide 62 radiation sensitizer 62 TriRima 62 inecalcitol 62 Trofex 62 azilsartan medoxomil 62 tumorigenicity 62 EVIZON TM 62 NEUMUNE 62 ADAMTS# 62 Diamyd ® 62 PD LID 62 JAK inhibitor 62 Zalypsis 62 Thalomid ® 62 Arikace 62 REP# 62 IAP inhibitor 62 FUSILEV enhances 62 CRLX# 62 retapamulin 62 sargramostim 62 postoperative chemotherapy 62 Sphingomab 62 AKT inhibitor 62 dasatinib Sprycel 62 HDL Selective Delipidation 62 Oral NKTR 62 trodusquemine 62 FTIs 62 vidofludimus 62 Civacir 62 Reports Preclinical Data 62 bronchodilatory 62 dosing cohort 62 BRAF inhibitors 62 GLP toxicology studies 62 Neuvenge 62 Cimzia TM 62 Tolvaptan 62 Arranon 62 Androxal TM 62 pancreatic prostate 62 verteporfin 62 generation nucleoside analog 62 lomitapide 62 B7 H3 62 LymphoStat B belimumab 62 Vascugel ® 62 Chemophase 62 vivo validation 62 metastatic neuroendocrine tumors 62 metreleptin 62 ELACYT 62 ARIKACE ™ 62 metastatic colorectal 62 OvaRex R 62 renal toxicity 62 rindopepimut 62 neuroprotective properties 62 TNF alpha selectively neutralizing 62 CCR1 62 gamma secretase inhibitor 62 neurotrophic 62 triphendiol 61 tanespimycin 61 calcitonin 61 thalidomide Thalomid 61 imatinib therapy 61 HGS ETR1 61 Triapine R 61 ATL# [001] 61 HepaLife PICM 61 liposomal formulation 61 Alferon N 61 Factor VIIa 61 PROSTVAC VF 61 novel oral anticoagulant 61 Kevetrin 61 Thorough QT 61 CaPre TM 61 HER2 expression 61 protein tyrosine phosphatase 1B 61 AAG geldanamycin analog 61 ImmunoVEX HSV2 61 Valortim ® 61 gemifloxacin 61 liposomal doxorubicin 61 PANVAC VF 61 multitargeted 61 Proellex TM 61 visilizumab 61 Ceplene/IL-2 61 squalamine 61 biologic DMARD 61 ACTEMRA TM 61 GHRH 61 cytoprotective 61 SPRYCEL ® 61 mouse xenograft models 61 maximally tolerated dose 61 Sudhir Agrawal D.Phil 61 bortezomib Velcade 61 midstage clinical 61 Capesaris 61 Proxinium TM 61 #I TM# 61 THR beta agonist 61 CCR5 antagonist 61 busulfan 61 AMD# [003] 61 PASI scores 61 LEP ETU 61 Perforomist ™ Inhalation Solution 61 drug GLPG# 61 SPIRIVA HandiHaler 61 Nicole Onetto MD 61 GLYX 61 phototoxicity 61 Interferon beta 61 colesevelam HCl 61 stent neointimal growth 61 interleukin IL -# 61 AZILECT ® 61 neuro protective 61 TELINTRA 61 fibrotic disease 61 FluCide 61 serum urate levels 61 silico prediction 61 NS#/#A protease 61 erythropoietic 61 tryptase 61 anti angiogenic agent 61 Technosphere Insulin 61 intestinal mucosal 61 Kinoid 61 untreated metastatic melanoma 61 torezolid phosphate 61 pharmacokinetic interactions 61 sorafenib Nexavar 61 PRESEPT study 61 Xelox 61 Solazed TM 61 Doxil ® 61 Alequel 61 Phase 1b clinical trials 61 angiogenesis inhibitor 61 Olaparib 61 Orphan Status 61 Intravenous CP 61 osteogenic 61 Bayer HealthCare Onyx Pharmaceuticals 61 SNT-MC#/idebenone 61 axitinib 61 bosutinib 61 A3 adenosine receptor 61 drug GAP #B# 61 successfully commercialize Iluvien 61 masitinib 61 antiangiogenic agents 61 TKM PLK1 61 LPA1 receptor 61 PrevOnco ™ 61 Cytolin ® 61 rhIGF-I/rhIGFBP-3 61 inhaled AAT 61 zileuton injection 61 R roscovitine 61 PLK1 SNALP 61 HCV replicon 61 APOPTONE 61 rosuvastatin #mg 61 novel histone deacetylase 61 CIMZIA TM certolizumab pegol 61 receptor tyrosine kinase inhibitor 61 thymalfasin 61 milatuzumab 61 AGILECT R 61 posaconazole 61 Aliskiren 61 hyperphenylalaninemia HPA due 61 nucleoside analogues 61 tolevamer 61 ThermoDox ® clinical 61 IMC #B 61 Cannabinor 61 Valortim 61 Anidulafungin 61 Nanobodies ® 61 lumiliximab 61 ISTODAX 61 PNP inhibitor 61 cilengitide 61 RhuDex ® 61 crizotinib PF # 61 BrachySil TM 61 gemcitabine Gemzar 61 immunotherapeutic vaccine 61 BRAF inhibitor 61 paclitaxel Taxol 61 TransVax ™ 61 Sym# 61 LymphoStat B TM 61 selective inhibition 61 Certolizumab pegol 61 oral clodronate 61 Prestara 61 chimeric monoclonal antibody 61 Cytolin R 61 Significant teratogenic 61 ANG# 61 chemopreventive agent 61 histone deacetylase HDAC inhibitor 61 ApoB SNALP 61 Apoptone 61 sunitinib Sutent 61 oral methylnaltrexone 61 OncoVex 61 mTOR inhibitors 61 DP b# 61 paricalcitol 61 elacytarabine 61 alfa 2a 61 Dapagliflozin 61 Pimavanserin 61 eniluracil 61 recurrent glioblastoma multiforme 61 lymphomas leukemias 61 secretory phospholipase A2 sPLA2 61 PGL# 61 EP #R 61 VAPRISOL 61 GRNCM1 61 potency selectivity 61 tezampanel 61 safinamide 61 Serdaxin 61 cardiac repolarization 61 Alagebrium 61 Lpathomab 60 PI3K/Akt pathway inhibitor 60 EndoTAGTM 1 60 Anthim 60 pharmacokinetic characteristics 60 Relivar 60 Tarvacin 60 fibrin deposition 60 talabostat 60 anidulafungin 60 Subgroup analysis 60 recurrent metastatic 60 HIF 1a 60 phase IIb clinical 60 BRIM2 60 skeletal metastases 60 ZFN modified 60 IMP# 60 phase IIb study 60 next generation URAT1 60 ANAVEX #-# [002] 60 olaparib 60 DCVax R 60 Aclidinium 60 MMP inhibitors 60 ERK signaling 60 Squalamine 60 drug ISA# 60 budesonide foam 60 p# activation 60 XP# XP# 60 trastuzumab Herceptin R 60 HDAC EGFR 60 PF # [002] 60 GFT# 60 prostanoid 60 orBec 60 tumor regressions 60 durable remissions 60 EDARBI 60 neuroinflammatory 60 HuMax EGFr 60 PDE4 inhibitor 60 haematologic 60 anti angiogenic therapy 60 Phase #b/#a trial 60 metastatic gastric 60 fusion enhancers 60 Raf MEK ERK 60 oral salmon calcitonin 60 elotuzumab 60 Pagoclone 60 tubulin inhibitor 60 KIACTA ™ 60 MEK inhibitor RDEA# 60 Lisofylline LSF 60 Perifosine 60 IGFBP 3 60 candidate CRLX# 60 velafermin 60 Fludara ® 60 MYLOTARG 60 ORENCIA R 60 Zysolin TM 60 Onalta ™ 60 synthetic retinoid 60 thymosin beta 4 60 mGluR5 NAM 60 ToGA 60 TTF Therapy 60 Fingolimod 60 pertuzumab 60 5 HT2C receptor 60 Natalizumab 60 cancer immunotherapies 60 tramiprosate Alzhemed TM 60 icatibant 60 EDEMA3 60 GVAX ® 60 apremilast 60 HMG CoA reductase inhibitors 60 ganetespib 60 immunodeficiency disorders 60 paclitaxel poliglumex 60 plasma kallikrein 60 Advagraf 60 chemosensitivity 60 recurrent glioma 60 tumor necrosis 60 bactericidal activity 60 solithromycin 60 Elocalcitol 60 acyclovir Lauriad R 60 VEGF receptor 60 PLX cells 60 papillary renal cell carcinoma 60 prospectively stratified 60 solid tumors ZYBRESTAT 60 potent anticancer 60 intranasal insulin 60 Src inhibitors 60 Plicera 60 pharmacokinetic equivalence 60 Tarvacin Anti Cancer 60 OncoVEX 60 CG# [003] 60 HIF PH inhibitors 60 IFN beta 60 Nanobody ® 60 atacicept 60 Alocrest 60 CA9 SCAN 60 CIPN 60 TACI Ig 60 surgical debulking 60 Xcytrin R 60 histamine dihydrochloride 60 Antioxidant supplements 60 hypercholesterolemic patients 60 SIRT1 activators 60 Mipomersen 60 huN# DM1 60 tezampanel NGX# 60 TELCYTA 60 Ixempra 60 Insegia 60 clusterin protein 60 Ocrelizumab 60 iniparib 60 zoledronate 60 prostate carcinoma 60 EOquin TM 60 Fx #A 60 ADAGIO study 60 systemic siRNA 60 CBLB# 60 eTag assays 60 novel nucleoside analog 60 class mGluR5 inhibitor 60 EDEMA3 trial 60 Fodosine 60 malignant ascites 60 potently inhibited 60 induced tumor regression 60 anti fibrotic 60 unresectable tumors 60 IMPDH inhibitor 60 isoproterenol 60 Alvesco R 60 rifalazil 60 Phase #/#a trial 60 IFN α 60 small molecule tyrosine 60 obatoclax 60 reduce serum phosphate 60 relapsed ALL 60 ZYBRESTAT fosbretabulin 60 gadobutrol 60 CD# CEA 60 erlotinib Tarceva ® 60 Hepatotoxicity 60 PRX# 60 enzastaurin 60 XL# anticancer compounds 60 dextofisopam 60 amifostine 60 AEG# 60 Bortezomib 60 dose proportionality 60 schizophrenia CIAS 60 preclinical toxicology 60 decitabine 60 HCV replication 60 hepatic fibrosis 60 RoACTEMRA 60 immunomodulatory 60 cardiotoxic 60 FOLPI 60 Valdoxan 60 Potelligent Technology 60 Pafuramidine 60 favorable pharmacokinetic 60 nonnucleoside reverse transcriptase inhibitors 60 transgene expression 60 Tasigna prolongs 60 Lyn kinase 60 Zemplar Capsules 60 Zoraxel 60 antiandrogen 60 axonal regeneration 60 NeuroVax TM 60 GeoVax vaccine 60 Safinamide 60 ACV1 60 Phase IIB 60 Homspera 60 ispinesib administered 60 Myocet 60 redox active 60 xenograft models 60 CD8 + cytotoxic 60 psoriatic arthritis PsA 60 interferon beta therapy 60 NS5A 60 limiting toxicity 60 Valortim R 60 Cardio Vascu Grow 60 SERCA2a 60 Toremifene 60 humanized monoclonal antibodies 60 CINTREDEKIN BESUDOTOX 60 asthma immunotherapeutic 60 dacetuzumab 60 Glypromate 60 pediatric malignancies 60 investigational monoclonal antibody 60 TRIOLEX 60 DiLA2 liposomes 60 Arimoclomol 60 DEB# 60 Thiovir 60 Achieves Primary Endpoint 60 TroVax ® 60 TH# [003] 60 nephrotoxicity 60 PEGylated Fab fragment 60 albiglutide 60 docetaxel Taxotere 60 Triolex 60 Nexavar sorafenib tablets 60 Generx TM 60 SIRT1 activation 60 eritoran 60 glucagon receptor 60 ARRY # 60 VELCADE melphalan 60 CMV vaccine 60 Fibrin MB 60 KRN# 60 urocortin 2 60 ATL# [002] 60 Aloxi injection 60 Hsp# inhibition 60 nanoviricides 60 Icatibant 60 temsirolimus 60 recombinant PSMA vaccine 60 Posiphen 60 BEXXAR Therapeutic Regimen 60 glioblastoma tumors 60 rilonacept 60 noninfectious uveitis 60 pamidronate 60 pharmacodynamic PD 60 Phase Ib clinical 60 TNFa 60 anti angiogenic drugs 60 plasma pharmacokinetics 60 relapsing remitting MS RRMS 60 INT# [002] 60 STRIDE PD 60 Pivotal Clinical Trial 59 Soliris eculizumab 59 TRO# 59 antiviral efficacy 59 docetaxel Taxotere ® 59 R#/MEM 59 anti CD3 59 targeting CD# 59 pharmacological chaperone 59 ancrod 59 metastatic malignant 59 dosing frequency 59 pegylated liposomal doxorubicin 59 Palifosfamide 59 statin monotherapy 59 RSD# oral 59 desvenlafaxine succinate 59 antiapoptotic 59 EGFR HER 59 dexpramipexole 59 dexanabinol 59 EGS# 59 IIa trial 59 Exelixis compounds 59 lucinactant 59 MyVax R 59 KNS # 59 azacitidine 59 multiple myeloma MM 59 mutated KRAS 59 LHRH antagonists 59 AA Amyloidosis 59 FOLOTYN ® 59 Protexia ® 59 imetelstat 59 lenalidomide dexamethasone 59 rufinamide 59 somatostatin 59 solanezumab 59 cleavable linker 59 antiangiogenic 59 JAK#/JAK# 59 relapsed MCL 59 OMNARIS Nasal Spray 59 ASONEP 59 inhibit replication 59 delipidation 59 acromegalic patients 59 mg BID dose 59 Ophena 59 rBChE 59 immuno modulatory 59 candidate TNFerade biologic 59 PKC# 59 Tumor Response 59 hormone receptor negative 59 vapreotide acetate 59 Phase 1a clinical 59 humanised monoclonal antibody 59 Muraglitazar 59 cardioprotection 59 experimental autoimmune encephalomyelitis 59 SinuNase ™ 59 Prodarsan R 59 ruxolitinib 59 alkylating agent 59 Allovectin 7 59 HIV coinfected 59 PHD2 59 HER2 positive cancers 59 EVIZON 59 Carfilzomib 59 PXD# 59 pCR 59 cytostatic 59 antitumor activity 59 ocular formulation 59 mediated inhibition 59 recurrent glioblastoma 59 AMPK activators 59 Enzastaurin 59 RNAi therapeutic targeting 59 OvaRex ® MAb 59 telomerase inhibitor 59 vemurafenib 59 cediranib 59 morphometric vertebral fractures 59 HIF 1α 59 Aptivus ® 59 diabetic neuropathic pain 59 remyelination 59 XOMA 3AB 59 TNF antagonist 59 immunomodulatory effects 59 rHuPH# 59 recurrent glioblastoma multiforme GBM 59 angiogenesis inhibition 59 CEACAM1 59 PORxin TM 59 apoptosis inducer 59 FOLFOX chemotherapy 59 ERK activation 59 IFN γ 59 ICA # 59 TBC# 59 Phase Ib IIa 59 taxane resistant 59 GAMMAGARD 59 Provecta TM 59 inhibit EGFR 59 PROMACTA 59 sulindac 59 M1 muscarinic 59 CMV infections 59 RGB # 59 Kei Utsugi researcher 59 AVI antiviral programs 59 IL 1Ra 59 PTHrP 59 standard chemotherapy regimen 59 prostate epithelial cells 59 vismodegib 59 serum phosphate 59 nanoviricide drug 59 MNTX 59 SomatoKine R 59 estramustine 59 Abbokinase 59 multi kinase inhibitor 59 microbiological eradication 59 DexaSite 59 DDP# 59 Initiates Enrollment 59 PDE# 59 Ceflatonin 59 personalized immunotherapy 59 Zybrestat 59 lintuzumab SGN 59 Zemiva TM 59 midstage trials 59 immunological responses 59 Anticalin ® 59 BioVant 59 Aeolus Pharmaceuticals Announces 59 davunetide intranasal AL 59 Warfarin Coumadin 59 patients receiving myelosuppressive 59 CINQUIL 59 perfusion MRI 59 motesanib 59 pegylated IFN 59 oral ridaforolimus 59 DFMO 59 exon skipping 59 Plenaxis TM 59 Microarray analysis 59 PRT# 59 Dose escalation 59 ESBA# 59 retinal vein occlusion induced 59 CHOP chemotherapy 59 Q#IR 59 trastuzumab DM1 T DM1 59 prednisone prednisolone 59 vivo efficacy 59 TriGrid ™ 59 proteasome inhibitors 59 goserelin 59 pharmacodynamic markers 59 oral PTH 59 Solazed 59 OMP #R# 59 radiographic progression 59 CYC# 59 BrachySil ™ 59 ELND# 59 myoblast therapy 59 Cloretazine R 59 dirucotide MBP# 59 Diamyd r vaccine 59 nucleotide analog 59 CRD5 59 BEXXAR 59 Virulizin R 59 tiapamil 59 Phase IIA 59 lapatinib Tykerb 59 AEGR 59 uPA 59 anticancer compound 59 advanced carcinoid 59 inhibit platelet function 59 OvaRex MAb 59 trabedersen 59 viral titers 59 antisense inhibition 59 histone deacetylase inhibitors 59 delafloxacin 59 ACE inhibitor ramipril 59 Cipralex ® 59 fumagillin nanoparticles 59 volociximab 59 adipiplon 59 MCSP respectively 59 investigational humanized monoclonal antibody 59 EFAPROXYN 59 RRMS patients 59 refractory metastatic 59 vosaroxin 59 Pazopanib 59 antiplatelet agent 59 familial hypercholesterolemia FH 59 defensin mimetic antibiotic 59 mTOR mammalian target 59 compound INCB# 59 MKC# 59 intranasal delivery 59 PEG IFN 59 benign prostatic hyperplasia enlarged 59 ticagrelor Brilinta 59 Radilex 59 R lenalidomide 59 nosocomial pneumonia 59 biliary tract cancer 59 beta 1a 59 MS relapses 59 Evoltra ® 59 nephrotoxic 59 intracoronary 59 CytoFabTM 59 Cx# [002] 59 MEK inhibitor 59 alemtuzumab Campath 59 ZFP TF 59 radezolid 59 APTIVUS r 59 canakinumab 59 CorVue ™ 59 TYSABRI natalizumab 59 ALN HTT 59 RG# [001]